Nov 16, 2018
The staggering failure rate of experimental drugs in clinical trials indicates that despite huge investments in novel technologies, productivity gains in the pharmaceutical industry remain elusive. The pharmaceutical industry is facing a serious innovation deficit.
The current biopharma model is therefore unsustainable and disruptive approaches are needed to remedy the status quo. It is incumbent upon the biomedical research community to harness the collective intelligence of pharma, biotech, academia, governmental agencies, non-profit research foundations and patient advocacy groups to accelerate innovation.
In part 2 of this series of 3 episodes, we discuss the core model.
Original article by Ibis Sanchez-Serrano, Dr Tom Pfeifer and Dr Rathnam Chaguturu
If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: